Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus R-CHOP vs R-CHOP in first-line DLBCL with TP53 mutation and PD-L1 expression
ChiCTR2200057623Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Complete response rate. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200057623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057623.